Loading
A phase 1/2 trial of Ramucirumab and Sacituzumab tirumotecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) is a phase 1/2 interventional study registered as NCT06445972 by Merck Sharp & Dohme LLC, with 210 participants planned, started 2024-08-07 and due to reach its primary completion in 2028-05-09. Interventions recorded: Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan, Rescue Medications and HER3-DXd.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/